Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Javelin Pharmaceuticals has received and published its UK pricing for Dyloject. Pricing was received from the Department of Health Pharmaceutical Price Regulation Scheme, which has accepted Javelin's proposal that the National Health Service tariff price for Dyloject be GBP48 per pack.
Subscribe to our email newsletter
Daniel Carr, CEO and CMO of Javelin, said: “Today is a watershed in Javelin’s evolution from a development company to a revenue-generating organization. Pricing publication marks the UK launch of Dyloject, our proprietary injectable NSAID for the treatment of acute moderate-to-severe pain. The Javelin sales force is now fully engaging hospital formulary decision makers in making the product available to prescribers within the hospital setting.”
Derek Gallacher, Javelin’s European managing director, said: “This decision is a very positive outcome for Javelin in the UK, coming as it does at a time of increasing price pressures. Based upon such pricing, we believe that Dyloject provides significant clinical and cost savings benefits to patients, healthcare providers and the National Health Service.”